By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Emergent BioSolutions 

2273 Research Boulevard
Suite 400
Rockville  Maryland  20850  U.S.A.
Phone: 301-795-1800 Fax: 301-795-1899

Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and therapeutics that assist the body’s immune system to prevent or treat disease. Emergent’s marketed product, BioThrax® (Anthrax Vaccine Adsorbed), is the only vaccine licensed by the U.S. Food and Drug Administration for the prevention of anthrax infection. Emergent’s development pipeline includes programs focused on anthrax, botulism, tuberculosis, typhoid, hepatitis B and chlamydia.

Key Statistics

Ownership: Public

Web Site: Emergent BioSolutions
Symbol: EBS

Company News
Emergent BioSolutions (EBS) To Hold Annual Meeting Of Stockholders Thursday May 25, 2017 At 9:00 AM EDT; Webcast Will Be Available 5/11/2017 11:25:20 AM
Emergent BioSolutions (EBS) Unveils Its Expanded Center For Innovation In Advanced Development And Manufacturing In Baltimore 5/10/2017 8:44:35 AM
Emergent BioSolutions (EBS) To Unveil Its Expanded Center For Innovation In Advanced Development And Manufacturing Supported Through Public-Private Partnership With BARDA 5/9/2017 10:44:58 AM
Emergent BioSolutions (EBS) Reports First Quarter 2017 Financial Results; Reaffirms 2017 Guidance 5/5/2017 11:40:36 AM
Emergent BioSolutions (EBS) To Release First Quarter 2017 Financial Results And Conduct A Conference Call On May 4, 2017 4/20/2017 8:37:33 AM
Aptevo Therapeutics (APVO) Release: Company Receives $20 Million Payment From Emergent BioSolutions (EBS) 1/13/2017 7:38:01 AM
Emergent BioSolutions (EBS) Announces Preliminary 2016 Financial Results And Provides 2017 Financial Outlook 1/9/2017 7:37:50 AM
Soligenix (SNGX) Announces Extension of Development Agreement With Emergent BioSolutions (EBS) 1/3/2017 6:58:18 AM
Emergent BioSolutions (EBS) Inks Anthrax Vaccine Deal Worth $1 Billion With the HHS 12/9/2016 6:09:02 AM
Integrated BioTherapeutics Announces Licensing Agreement With Emergent BioSolutions (EBS) For Development Of Equine Immunoglobulin Therapeutics For Filovirus Infections 11/15/2016 8:11:49 AM